Video interview with CEO Martin Vidaeus, August 27, 2019
CEO Martin Vidaeus presented the status of Redwood Pharma's Phase II trial for its RP101 program - a new treatment for post-menopausal women suffering from chronic, moderate to severe Dry Eye Disease. About RP101RP101 is the company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials in the US. The active substance for the first time has been formulated in IntelliGel to control its release, reduce dosing and